Technical Analysis for OCUL - Ocular Therapeutix, Inc.

Grade Last Price % Change Price Change
D 14.97 -2.67% -0.41
OCUL closed down 2.67 percent on Thursday, May 13, 2021, on 1.13 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Flat Down Down
Historical OCUL trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
180 Bearish Setup Bearish Swing Setup -2.67%
Slingshot Bearish Bearish Swing Setup -2.67%
NR7 Range Contraction -2.67%
200 DMA Support Bullish -4.95%
MACD Bearish Signal Line Cross Bearish -1.19%
20 DMA Resistance Bearish -7.88%
Calm After Storm Range Contraction -7.88%
Inside Day Range Contraction -7.88%
Fell Below 20 DMA Bearish -5.67%
Older End-of-Day Signals for OCUL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% about 17 hours ago
Down 3% about 17 hours ago
Fell Below 200 DMA about 17 hours ago
200 DMA Support about 19 hours ago
60 Minute Opening Range Breakdown about 19 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Ocular Therapeutix, Inc. Description

Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapies based on its proprietary hydrogel platform technology for treating eye diseases and conditions. The company offers ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions made during cataract surgery Its lead product candidates comprise OTX-DP, which is in Phase III clinical trials for the treatment of post-surgical ocular inflammation and pain; and OTX-TP that is in Phase II clinical trials for the treatment of glaucoma and ocular hypertension. The company's earlier stage product candidates include OTX-DP, which is in Phase II clinical trials for the treatment of allergic conjunctivitis; OTX-MP that has completed Phase I clinical trials for the treatment of bacterial conjunctivitis; and Anti-VEGF hydrogel depot, which is in preclinical testing for the treatment of wet AMD. Ocular Therapeutix, Inc. sells its ReSure Sealant through a network of independent medical device distributors in the United States. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Eye Pain Inflammation Hypertension Clinical Trial Sealant Glaucoma Platform Technology Eye Disease Incision Cataract Eye Diseases Treatment Of Glaucoma Cornea Incisions Allergic Conjunctivitis Cataract Surgery Allergology Ocular Hypertension Post Surgical Ocular Inflammation

Is OCUL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 24.3
52 Week Low 5.85
Average Volume 1,086,874
200-Day Moving Average 14.95
50-Day Moving Average 17.25
20-Day Moving Average 16.10
10-Day Moving Average 16.29
Average True Range 1.24
ADX 20.02
+DI 17.46
-DI 31.56
Chandelier Exit (Long, 3 ATRs ) 16.07
Chandelier Exit (Short, 3 ATRs ) 17.89
Upper Bollinger Band 18.35
Lower Bollinger Band 13.85
Percent B (%b) 0.25
BandWidth 27.95
MACD Line -0.41
MACD Signal Line -0.30
MACD Histogram -0.1076
Fundamentals Value
Market Cap 1.07 Billion
Num Shares 71.4 Million
EPS -1.79
Price-to-Earnings (P/E) Ratio -8.36
Price-to-Sales 74.23
Price-to-Book 124.04
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.01
Resistance 3 (R3) 16.98 16.27 16.67
Resistance 2 (R2) 16.27 15.75 16.29 16.56
Resistance 1 (R1) 15.62 15.43 15.27 15.65 16.44
Pivot Point 14.91 14.91 14.73 14.93 14.91
Support 1 (S1) 14.26 14.39 13.91 14.29 13.50
Support 2 (S2) 13.55 14.07 13.57 13.38
Support 3 (S3) 12.90 13.55 13.27
Support 4 (S4) 12.93